CDC recommends Arexvy for the prevention of RSV disease

Having just last month become the first company to get US approval in the therapy class, UK pharma major GSK (LSE: GSK) revealed that US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of it Arexvy (respiratory syncytial virus vaccine, adjuvanted) in adults aged 60 and older using shared clinical decision making.

Shared clinical decision making empowers patients in consultation with their healthcare providers to determine whether RSV vaccination is appropriate for them, GSK noted.

There are an estimated 55.8 million people aged 65 and older in the USA who are at increased risk of RSV, a common, contagious virus that can lead to serious respiratory illness. RSV causes around 177,000 hospitalizations and an estimated 14,000 deaths in this age group in the USA each year. For adults 60 and older, data suggest an increased risk for severe RSV infection that can lead to hospitalization. Older adults, including those with underlying medical conditions, such as chronic heart disease, chronic lung disease or diabetes, are at high risk of severe RSV illness and account for the majority of RSV hospitalizations.